TOKYO, May 24, 2019 - Elekta (EKTA-B.ST) announced today that its Elekta Unity magnetic resonance radiation therapy system has been approved for clinical use in Japan.

Elekta Unity combines two technologies: a state-of-the-art 1.5T MRI scanner and a best-in-class 7 MV linear accelerator, driven by breakthrough real-time adaptive radiotherapy software. It provides the ability to reshape the dose based on daily changes in shape, size and position of the tumor and surrounding healthy anatomy, as visualized with MRI, and then enables accurate dose delivery with real-time visualization of the tumor. 

"With the introduction of Unity, hospitals and clinicians in Japan now have access to unsurpassed precision radiation medicine," said Charles Schanen, President of Elekta K.K. (Japan). "More importantly, we anticipate this innovative technology to improve the outcomes for the more than one million people diagnosed with cancer in Japan."

To learn more, visit elekta.com/Unity (http://www.elekta.com/unity).

Elekta Unity is CE marked and 510(k) cleared. It is not commercially available in all markets. 

# # #

For further information, please contact:
Oskar Bosson, Global EVP Corporate Communications and Investor Relations
Tel: +46 70 410 7180, e-mail: Oskar.Bosson@elekta.com
Time zone: CET: Central European Time 

Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, e-mail: raven.canzeri@elekta.com
Time zone: EST: Eastern Standard Time

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com (http://www.elekta.com) or follow @Elekta (https://twitter.com/Elekta)on Twitter.